CoChat

The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy

Open access
Bilich, Tatjana, Nelde, Annika, Bichmann, Leon, Roerden, Malte, Salih, Helmut R., Kowalewski, Daniel J., Schuster, Heiko, Tsou, Chih-Chiang, Marcu, Ana, Neidert, Marian C., Lübke, Maren, Rieth, Jonas, Schemionek, Mirle, Brümmendorf, Tim H., Vucinic, Vladan, Niederwieser, Dietger, Bauer, Jens, Märklin, Melanie, Peper, Janet K., Klein, Reinhild, Kohlbacher, Oliver, Kanz, Lothar, Rammensee, Hans-Georg, Stevanović, Stefan, Walz, Juliane S. · 2019 · Blood
Cited by 75

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Antileukemia immunity plays an important role in disease control and maintenance of tyrosine kinase inhibitor (TKI)-free remission in chronic myeloid leukemia (CML). Thus, antigen-specific immunotherapy holds promise for strengthening immune control in CML but requires the identification of CML-associated targets. In this study, we used a mass spectrometry–based approach to identify naturally presented HLA class I– and class II–restricted peptides in primary CML samples. Comparative HLA ligandome profiling using a comprehensive dataset of different hematological benign specimens and samples from CML patients in deep molecular remission delineated a panel of novel frequently presented CML-exclusive peptides. These nonmutated target antigens are of particular relevance because our extensive data-mining approach suggests the absence of naturally presented BCR-ABL– and ABL-BCR–derived HLA-restricted peptides and the lack of frequent tumor-exclusive presentation of known cancer/testis and leukemia-associated antigens. Functional characterization revealed spontaneous T-cell responses against the newly identified CML-associated peptides in CML patient samples and their ability to induce multifunctional and cytotoxic antigen-specific T cells de novo in samples from healthy volunteers and CML patients. Thus, these antigens are prime candidates for T-cell–based immunotherapeutic approaches that may prolong TKI-free survival and even mediate cure of CML patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2018-07-866830

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 75

Metadata

Authors
Bilich, T., Nelde, A., Bichmann, L., Roerden, M., Salih, H. R., Kowalewski, D. J., Schuster, H., Tsou, C.-C., Marcu, A., Neidert, M. C., Lübke, M., Rieth, J., Schemionek, M., Brümmendorf, T. H., Vucinic, V., Niederwieser, D., Bauer, J., Märklin, M., Peper, J. K., Klein, R., Kohlbacher, O., Kanz, L., Rammensee, H.-G., Stevanović, S., & Walz, J. S.
Venue
Blood
Published
2019-02-07
Volume
133
Issue
6
Pages
550-565
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2903859834
Cited by
75
References
7
FWCI
3.49
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. https://app.cochat.ai/papers/10.1182/blood-2018-07-866830
The paper
Bilich, T., Nelde, A., Bichmann, L., Roerden, M., Salih, H. R., Kowalewski, D. J., Schuster, H., Tsou, C.-C., Marcu, A., Neidert, M. C., Lübke, M., Rieth, J., Schemionek, M., Brümmendorf, T. H., Vucinic, V., Niederwieser, D., Bauer, J., Märklin, M., Peper, J. K., . . . Walz, J. S. (2019). The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. Blood. https://doi.org/10.1182/blood-2018-07-866830

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.